Prof Nancy Haigwood

Prof Nancy Haigwood

Oregon Health and Science University, Portland, Oregon, USA valls_onprc_haigwood_728

Visit co-ordinated by Gabrielle Belz


14 February Seminar (12pm, Finkel theatre) and meetings at the John Curtin School of Medical Research, Canberra (host: Ian Cockburn)

15-16 February Lorne Infection & Immunity

20 February Combined seminar and meetings at the Burnet Institute and Peter Doherty Institute, Melbourne (host: Heidi Drummer)

21 February Seminar and meetings at Monash Medical Centre, Melbourne (host: Andrea Johannessen)

23 February Seminar and meetings atUniversity of Queensland (host: Sumaira Hasnain)


For the last 30 years Prof Haigwood has been actively engaged in vaccine discovery and immunotherapy research for in nonhuman primate (NHP) models for HIV/AIDS. Prof Haigwood co-developed one of the first HIV vaccines, gp120 produced in CHO cells, while at Chiron Corporation (now Novartis) and has maintained a continuously funded laboratory that is focused on antibody-based therapies and Envelope-based vaccines to elicit protective antibodies. Since leaving industry in 1997, Prof Haigwood has led numerous and continuing individual and collaborative program grants as Principal Investigator, including serving as PI of a P01 “HIVRAD” vaccine grant to discover novel HIV Envelope immunogens. Expertise in the laboratory extends to DNA-based and viral vaccines, as well as recombinant monomeric and trimeric antigen design and production in 293 cells (and purification) for use in vaccine studies. Prof Haigwood's laboratory has recently shown that potent human neutralizing monoclonal antibodies can change the course of SHIV infection in infant macaques, directly killing newly established infected cells in vivo and preventing the establishment of a permanent viral reservoir.